Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Rome 00161, Italy.
Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome 00123, Italy.
World J Gastroenterol. 2020 May 28;26(20):2669-2681. doi: 10.3748/wjg.v26.i20.2669.
Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease and currently the most common cause of incidental abnormal liver tests. The pathogenesis of NAFLD is multifactorial and many mechanisms that cause fatty liver infiltration, inflammation, oxidative stress and progressive fibrosis have been proposed. Obstructive sleep apnea (OSA) may be linked with the pathogenesis and the severity of NAFLD.
To study the association between NAFLD and OSA considering also the efficacy of continuous positive airway pressure (CPAP) treatment.
A PubMed search was conducted using the terms "non-alcoholic fatty liver disease AND (obstructive sleep apnea OR obstructive sleep disorders OR sleep apnea)". Research was limited to title/abstract of articles published in English in the last 5 years; animal and child studies, case reports, commentaries, letters, editorials and meeting abstracts were not considered. Data were extracted on a standardized data collection table which included: First author, publication year, country, study design, number of patients involved, diagnosis and severity of OSA, diagnosis of NAFLD, patient characteristics, results of the study.
In total, 132 articles were initially retrieved on PubMed search and 77 in the last five years. After removal of irrelevant studies, 13 articles were included in the qualitative analysis. There was a total of 2753 participants across all the studies with a mean age between 42 and 58 years. The proportion of males ranged from 21% to 87.9% and the mean body mass index ranged from 24.0 to 49.9 kg/m. The results of this review showed an increased prevalence of NAFLD in patients with diagnosis of OSA, even in the absence of coexisting comorbidities such as obesity or metabolic syndrome. Furthermore, the severity of NAFLD is associated with the increase in OSA severity. Effective CPAP treatment, although not always decisive, may stabilize or slow NAFLD progression with benefits on metabolic and cardiovascular functions.
In NAFLD patients, although asymptomatic, it is recommended to systematically perform polysomnography in order to early and better treat them before the development of potentially life threatening systemic dysfunctions.
非酒精性脂肪性肝病(NAFLD)是一种新兴的肝脏疾病,目前是偶然发现的异常肝脏试验的最常见原因。NAFLD 的发病机制是多因素的,许多导致脂肪肝浸润、炎症、氧化应激和进行性纤维化的机制已经被提出。阻塞性睡眠呼吸暂停(OSA)可能与 NAFLD 的发病机制和严重程度有关。
研究 NAFLD 与 OSA 之间的关系,同时考虑持续气道正压通气(CPAP)治疗的效果。
在 PubMed 上使用术语 "非酒精性脂肪性肝病 AND(阻塞性睡眠呼吸暂停或阻塞性睡眠障碍或睡眠呼吸暂停)" 进行搜索。研究仅限于在过去 5 年内以英文发表的文章的标题/摘要;动物和儿童研究、病例报告、评论、信件、社论和会议摘要不被考虑。数据是在一个标准化的数据采集表上提取的,其中包括:第一作者、发表年份、国家、研究设计、涉及的患者人数、OSA 的诊断和严重程度、NAFLD 的诊断、患者特征、研究结果。
在 PubMed 搜索中最初检索到 132 篇文章,其中 77 篇是在过去 5 年内发表的。在去除不相关的研究后,有 13 篇文章被纳入定性分析。所有研究共有 2753 名参与者,平均年龄在 42 至 58 岁之间。男性比例从 21%到 87.9%不等,平均体重指数从 24.0 到 49.9kg/m 不等。本综述的结果表明,即使没有肥胖或代谢综合征等共存合并症,诊断为 OSA 的患者中 NAFLD 的患病率也会增加。此外,NAFLD 的严重程度与 OSA 严重程度的增加有关。有效的 CPAP 治疗虽然并不总是决定性的,但可能会稳定或减缓 NAFLD 的进展,对代谢和心血管功能有好处。
在 NAFLD 患者中,即使没有症状,也建议系统地进行多导睡眠图检查,以便在潜在的危及生命的全身功能障碍发生之前及早更好地治疗他们。